United States - English - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - baytril® (brand of enrofloxacin)taste tabs® antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. baytril antibacterial tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or gia

United States - English - NLM (National Library of Medicine)

aspen veterinary resources - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - indications: cattle - single-dose therapy: quellaxcin™ 100 is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis in beef and non-lactating dairy cattle; and for the control of brd in beef and non-lactating dairy cattle at high risk of developing brd associated with m. haemolytica, p. multocida, h. somni and m. bovis. cattle - multiple-day therapy: quellaxcin™ 100 is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida andhistophilus somni in beef and non-lactating dairy cattle. swine: quellaxcin™ 100 is indicated for the treatment and control of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis, streptococcus suis, bordetella bronchiseptica and mycoplasma hyopneumoniae . quellaxcin™ 100 is indicated for the control of colibacillosis in groups

United States - English - NLM (National Library of Medicine)

bayer healthcare, llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - baytril® 100-ca1 is indicated for the treatment of clinical anaplasmosis associated with anaplasma marginale in replacement dairy heifers under 20 months of age and all classes of beef cattle except beef calves less than 2 months of age and beef bulls intended for breeding (any age). not for use in any other class of dairy cattle or in veal calves.

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) -

United States - English - NLM (National Library of Medicine)

sparhawk laboratories, inc - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - cattle-single-dose therapy:  enrofloxacin 100 is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis in beef and non-lactating dairy cattle; and for the control of brd in beef and non-lactating dairy cattle at high risk of developing brd associated with m. haemolytica, p. multocida, h. somni and m. bovis . cattle-multiple-day therapy:  enrofloxacin 100 is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida and histophilus somni in beef and non-lactating dairy cattle. swine:  enrofloxacin 100 is indicated for the treatment and control of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis, streptococcus suis, bordetella bronchiseptica and mycoplasma hyopneumoniae.  enrofloxacin 100 is indicated for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with escherichia coli has been diagnosed.

United States - English - NLM (National Library of Medicine)

mwi/vetone - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

United States - English - NLM (National Library of Medicine)

aspen veterinary resources®, ltd - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

United States - English - NLM (National Library of Medicine)

butler animal health supply, llc dba covetrus north america - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - cattle - single-dose therapy: enrofloxacin 100 injection is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis in beef and non-lactating dairy cattle; and for the control of brd in beef and non-lactating dairy cattle at high risk of developing brd associated with m. haemolytica, p. multocida, h. somni and m. bovis. cattle - multiple-daytherapy: enrofloxacin 100 injection is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida and histophilus somni in beef and non-lactating dairy cattle. swine: enrofloxacin 100 injection is indicated for the treatment and control of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis, streptococcus suis, bordetella bronchiseptica and mycoplasma hyopneumoniae. enrofloxacin 100 injection is indicated for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with escherichia coli has been diagnosed.

United States - English - NLM (National Library of Medicine)

felix pharmaceuticals private limited - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - cattle - single-dose therapy:  enrofloxacin 100 mg/ml is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica , pasteurella multocida, histophilus somni and mycoplasma bovis in beef and non-lactating dairy cattle; and for the control of brd in beef and non-lactating dairy cattle at high risk of developing brd associated with m. haemolytica, p. multocida, h. somni and m. bovis. cattle - multiple-day therapy:  enrofloxacin 100 mg/ml is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida and histophilus somni in beef and non-lactating dairy cattle. swine: enrofloxacin 100 mg/ml is indicated for the treatment and control of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis, streptococcus suis, bordetella bronchiseptica and mycoplasma hyopneumoniae. enrofloxacin 100 mg/ml is indicated for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with escherichia coli has been diagnosed.

United States - English - NLM (National Library of Medicine)

norbrook laboratories limited - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 100 mg in 1 ml - cattle - single-dose therapy: enroflox 100 is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis in beef and non-lactating dairy cattle; and for the control of brd in beef and non-lactating dairy cattle at high risk of developing brd associated with m. haemolytica, p. multocida, h. somni and m. bovis . cattle - multiple-day therapy: enroflox 100 is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida and histophilus somni in beef and non-lactating dairy cattle. swine: enroflox 100 is indicated for the treatment and control of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis, streptococcus suis , bordetella bronchiseptica and mycoplasma hyopneumoniae . enroflox 100 is indicated for the control of colibacillosis in groups or pens of weaned pig